查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1830986

过动症治疗市场

ADHD Therapeutics Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

2024 年，ADHD 治疗市场价值约为 314.2 亿美元，预计到 2031 年将成长至 662.7 亿美元，2025 年至 2031 年的复合年增长率预计为 10.8%。

市场洞察与分析师观点：注意力不足过动症 (ADHD) 是一种多方面的神经发育障碍，会影响个体集中註意力、控制衝动行为和控制过动症的能力。虽然此病主要在儿童期诊断，但症状可能延续至青少年期和成年期。 ADHD 的治疗通常采用综合策略，包括行为疗法、教育支持以及兴奋剂和非兴奋剂等药物治疗。

过动症（ADHD）盛行率的上升和治疗药物需求的增加是推动市场成长的关键因素。然而，ADHD药物的副作用及其有限的疗效对ADHD治疗市场的扩张构成了挑战。

成长因素与挑战：根据美国疾病管制与预防中心（CDC）2022年2月发布的报告，2016年至2019年，美国约有600万3至17岁儿童被诊断为ADHD，占总人口的9.8%。此外，PubMed Central 2022年发表的一项研究表明，全球5%至7.2%的儿童和2.5%至6.7%的成年人患有ADHD。最近的估计表明，美国青少年的盛行率明显更高，约为8.7%或530万人。虽然传统上ADHD被认为是一种儿童疾病，但近90%的ADHD儿童在成年后仍会持续出现症状。此外，研究发现，75%的成年ADHD患者在儿童时期未被诊断出来。过动症 (ADHD) 常伴随焦虑、忧郁、学习障碍和药物滥用等併发症，使治疗更加复杂，需要采取综合疗法来应对 ADHD 症状和相关疾病。建议使用精神兴奋剂和非兴奋剂等药物来帮助儿童在日常生活中控制 ADHD 症状，并规范可能影响其生活各个方面（包括人际关係和学业表现）的行为。因此，这些因素正在推动对 ADHD 药物的需求，从而提升 ADHD 治疗药物的市场份额。

然而，由于症状缓解效果有限且副作用较大，ADHD 治疗市场的成长受到了阻碍。精神兴奋剂的常见副作用包括食慾下降、失眠、焦虑加剧、易怒、胃痛和头痛。此外，当药物疗效减弱时，ADHD 症状可能会復发，导致“反弹”，甚至可能更加严重。

策略洞察报告细分和范围：「ADHD 治疗市场分析」是透过检查以下细分进行的：药物类型、年龄层和配销通路。

分段分析：ADHD 治疗市场依药物类型分为兴奋剂药物和非兴奋剂药物。

2022 年，兴奋剂类药物占据了 ADHD 治疗市场的较大份额，预计 2022 年至 2030 年期间的复合年增长率将更高。

2022年及2030年ADHD治疗市场（依药物类型划分）依年龄层划分，ADHD治疗市场分为儿童及青少年及成人两大类。 2022年，儿童及青少年类药物占据了更大的市场份额，而成人类药物预计在2022年至2030年期间将经历更高的复合年增长率。

在分销通路方面，ADHD治疗市场分为医院药局、零售药局和电商。 2022年，医院药房占据了最大的市场份额，预计在2022年至2030年期间将实现最高的复合年增长率。

区域分析：ADHD 治疗市场报告分析的主要地区包括北美、欧洲、亚太、南美和中美以及中东和非洲。

2022 年，北美占据全球市场最大份额。在北美，美国在 2022 年占据了最大的市场份额，预计在 2022 年至 2030 年期间仍将保持领先地位。 ADHD 治疗市场的成长主要得益于美国 ADHD 的高盛行率。根据 Cingulate 的数据，2022 年约有 640 万名 4 至 17 岁的儿童和青少年被诊断出患有 ADHD。其中，超过 80% 的人正在接受治疗，约 65% 的人在成年后仍会继续出现 ADHD 症状。此外，患者负担能力的提高、优惠的报销政策以及对可用药物的认识提高等因素预计将进一步推动市场成长。

亚太地区是过动症（ADHD）治疗领域成长最快的市场，这得益于关键产业参与者的参与以及旨在开发和推广新产品的各种策略性倡议。例如，2020年6月，大冢製药株式会社和大冢製药开发与商业化公司宣布了两项为期六週的3期临床试验的积极成果，这些试验评估了口服西他那法定（centanafadine）的有效性、安全性和耐受性。西他那法定是一种针对成人ADHD患者的新型实验性药物。该公司也计划研究西他那法定对ADHD儿童的疗效，并与美国食品药物管理局（FDA）商讨后续步骤。

产业发展与未来机会：ADHD治疗市场的预测可以帮助利害关係人制定成长策略。市场主要参与者采取的关键措施包括：

2023年9月，Cingulate Inc. 发表了其主要候选药物 CTx-1301（右哌甲酯）用于治疗成人多动症的有效性和安全性的3期临床研究结果。该公司采用其专利的精准定时释放 (PTR) 药物递送平台技术，开发一系列下一代医药产品。研究结果于 9 月 8 日在田纳西州纳许维尔举行的第 36 届年度心理学大会上发表。 2022 年 3 月，久光製药株式会社的全资子公司 Noven Pharmaceuticals, Inc. 的 XELSTRYM（右旋安非他明）透皮系统 CII 获得美国食品药物管理局 (FDA) 批准，用于治疗成人和 6 岁及以上儿童患者的 ADHD。 2021 年 7 月，Corium, Inc. 在美国推出了 AZSTARYS，这是一种结合了舍曲林 (SDX) 和右旋哌甲酯 (d-MPH) 的创新药物，用于 6 岁及以上患者的症状治疗。 AZSTARYS 于 2021 年 3 月获得 FDA 批准，由两种药物组合组成：70% 缓释 d-MPH SDX 前药（附表 IV）和 30% 速释 d-MPH（附表 II）。 2021 年 4 月，Supernus Pharmaceuticals, Inc. 宣布美国 FDA 已批准 Qelbree（维洛沙嗪缓释胶囊）用于治疗 6 至 17 岁患者的 ADHD。竞争格局和主要公司：ADHD 治疗市场报告中介绍的主要参与者包括 Amneal Pharmaceuticals, Inc.；诺华公司；辉瑞公司；礼来公司；Noven Pharmaceuticals, Inc.；杨森製药公司；强生服务公司；Corium Inc；Adlon Therapeutics LP；和 Teva Pharmaceutical Industries Ltd.。这些公司实施产品开发策略以满足客户日益增长的需求，使他们能够维持品牌声誉。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：ADHD治疗市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：注意力不足过动症（ADHD）治疗市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：注意力不足过动症治疗市场－全球市场分析

  • ADHD 治疗 - 全球市场概览
  • ADHD 治疗 - 全球市场及 2030 年预测

第 7 章：注意力不足过动症 (ADHD) 治疗市场 - 收入分析 - 按药物类型，2020-2030 年

  • 概述
  • 兴奋剂
  • 非兴奋剂

第 8 章：注意力不足过动症 (ADHD) 治疗市场 - 收入分析 - 按年龄组，2020-2030 年

  • 概述
  • 儿童和青少年
  • 成年人

第 9 章：注意力不足过动症 (ADHD) 治疗市场 - 收入分析 - 按配销通路，2020-2030 年

  • 概述
  • 医院药房
  • 零售药局
  • 电子商务

第 10 章：ADHD 治疗市场 - 收入分析，2020-2030 年 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 12 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 13 章：注意力不足过动症 (ADHD) 治疗市场 - 主要公司简介

  • Amneal Pharmaceuticals, Inc
  • Novartis AG
  • Pfizer, Inc.
  • Eli Lilly and Company
  • Noven Pharmaceuticals, Inc.
  • Janssen Pharmaceuticals, Inc
  • Johnson and Johnson Services, Inc.
  • Corium Inc
  • Adlon Therapeutics L.P
  • Teva Pharmaceutical Industries Ltd

第 14 章：附录

简介目录
Product Code: TIPRE00003833

The ADHD therapeutics market was valued at approximately US$ 31.42 billion in 2024 and is projected to grow to US$ 66.27 billion by 2031, with an estimated CAGR of 10.8% from 2025 to 2031.

Market Insights and Analyst Perspective:Attention deficit/hyperactivity disorder (ADHD) is a multifaceted neurodevelopmental disorder that impacts an individual's capacity to concentrate, manage impulsive actions, and control hyperactivity. While it is primarily diagnosed in childhood, symptoms can extend into adolescence and adulthood. Treatment for ADHD typically employs a comprehensive strategy that includes behavioral therapy, educational support, and medications such as stimulants and non-stimulants.

The increasing prevalence of ADHD and the rising demand for therapeutic drugs are key factors driving market growth. However, the side effects linked to ADHD medications and their limited effectiveness pose challenges to the expansion of the ADHD therapeutics market.

Growth Factors and Challenges:According to a report from the Centers for Disease Control and Prevention (CDC) published in February 2022, around 6 million children aged 3 to 17 in the US were diagnosed with ADHD, representing 9.8% of the population from 2016 to 2019. Furthermore, a study published by PubMed Central in 2022 indicated that ADHD affects 5 to 7.2% of children and 2.5 to 6.7% of adults globally. Recent estimates suggest that the prevalence among adolescents in the US is significantly higher, at about 8.7% or 5.3 million. Although ADHD has been traditionally viewed as a childhood disorder, nearly 90% of children with ADHD continue to exhibit symptoms into adulthood. Additionally, 75% of adults with ADHD were not diagnosed during childhood, as per research findings. ADHD is often accompanied by comorbid conditions such as anxiety, depression, learning disabilities, and substance abuse, complicating treatment and necessitating a comprehensive approach that addresses both ADHD symptoms and these associated conditions. Medications like psychostimulants and non-stimulants are recommended to help children manage their ADHD symptoms in daily life and regulate behaviors that may disrupt various aspects of their lives, including personal relationships and academic performance. Consequently, these factors are driving the demand for ADHD medications, thereby enhancing the market share of ADHD therapeutics.

Nonetheless, the growth of the ADHD therapeutics market is hindered by the limited symptom relief and the side effects associated with these treatments. Common side effects of psychostimulant medications include reduced appetite, insomnia, heightened anxiety, increased irritability, stomach pain, and headaches. Additionally, when the medication's effects diminish, ADHD symptoms may re-emerge, leading to a "rebound" effect that can be more severe.

Strategic Insights

Report Segmentation and Scope:The "ADHD therapeutics market analysis" has been conducted by examining the following segments: drug type, age group, and distribution channel.

Segmental Analysis:The ADHD therapeutics market is categorized by drug type into stimulants and non-stimulant medications.

The stimulant drug segment accounted for a larger share of the ADHD therapeutics market in 2022 and is expected to exhibit a higher CAGR from 2022 to 2030.

ADHD Therapeutics Market by Drug Type - 2022 and 2030By age group, the ADHD therapeutics market is divided into pediatric & adolescent and adult segments. The pediatric & adolescent segment held a larger market share in 2022, while the adult segment is projected to experience a higher CAGR from 2022 to 2030.

Regarding distribution channels, the ADHD therapeutics market is segmented into hospital pharmacies, retail pharmacies, and E-commerce. In 2022, the hospital pharmacies segment captured the largest market share and is expected to achieve the highest CAGR during the period from 2022 to 2030.

Regional Analysis:The major regions analyzed for the ADHD therapeutics market report include North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

In 2022, North America held the largest share of the global market. Within North America, the US accounted for the largest market share in 2022 and is projected to maintain its leading position from 2022 to 2030. The growth of the ADHD therapeutics market is significantly driven by the high prevalence of ADHD in the US. According to Cingulate, approximately 6.4 million children and adolescents aged 4 to 17 were diagnosed with ADHD in 2022. Of this group, over 80% are receiving treatment, and about 65% continue to experience ADHD symptoms into adulthood. Additionally, factors such as improved patient affordability, favorable reimbursement policies, and heightened awareness of available medications are expected to further propel market growth.

Asia Pacific is the fastest-growing market for ADHD, attributed to the presence of key industry players and various strategic initiatives aimed at developing and marketing new products. For instance, in June 2020, Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. announced positive outcomes from two six-week phase 3 clinical trials evaluating the effectiveness, safety, and tolerability of oral centanafadine, a new experimental drug intended for adult patients diagnosed with ADHD. The company also plans to investigate the effects of centanafadine in children with ADHD and discuss subsequent steps with the US Food and Drug Administration.

Industry Developments and Future Opportunities:The forecast for the ADHD therapeutics market can assist stakeholders in formulating their growth strategies. Key initiatives undertaken by major players in the market include:

In September 2023, Cingulate Inc. reported results from its Phase 3 study on the efficacy and safety of its lead candidate, CTx-1301 (dexmethylphenidate), for treating ADHD in adults. The company employs its patented Precision Timed Release (PTR) drug delivery platform technology to develop a pipeline of next-generation pharmaceutical products. The results were presented on September 8th at the 36th Annual Psych Congress in Nashville, TN.

In March 2022, Noven Pharmaceuticals, Inc., a wholly owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., received approval from the US Food and Drug Administration (FDA) for its XELSTRYM (dextroamphetamine) transdermal system, CII, for the treatment of ADHD in adults and pediatric patients aged six years and older.

In July 2021, Corium, Inc. launched AZSTARYS, an innovative medication that combines Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) in the US for the symptomatic treatment of patients aged 6 years and older. AZSTARYS received FDA approval in March 2021 and consists of a combination of two types of medication: 70% extended-release prodrug of d-MPH SDX (Schedule IV) and 30% immediate-release d-MPH (Schedule II).

In April 2021, Supernus Pharmaceuticals, Inc. announced that the US FDA had approved Qelbree (viloxazine extended-release capsules) for the treatment of ADHD in patients aged 6 to 17.

Competitive Landscape and Key Companies:Key players profiled in the ADHD therapeutics market report include Amneal Pharmaceuticals, Inc.; Novartis AG; Pfizer, Inc.; Eli Lilly and Company; Noven Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson Services, Inc.; Corium Inc; Adlon Therapeutics LP; and Teva Pharmaceutical Industries Ltd. These companies implement product development strategies to meet the increasing demands of customers, enabling them to sustain their brand reputation.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. ADHD Therapeutics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. ADHD Therapeutics Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. ADHD Therapeutics Market - Global Market Analysis

  • 6.1 ADHD Therapeutics - Global Market Overview
  • 6.2 ADHD Therapeutics - Global Market and Forecast to 2030

7. ADHD Therapeutics Market - Revenue Analysis (USD Million) - By Drug Type, 2020-2030

  • 7.1 Overview
  • 7.2 Stimulants
  • 7.3 Non-Stimulants

8. ADHD Therapeutics Market - Revenue Analysis (USD Million) - By Age Group, 2020-2030

  • 8.1 Overview
  • 8.2 Pediatric and Adolescent
  • 8.3 Adults

9. ADHD Therapeutics Market - Revenue Analysis (USD Million) - By Distribution Channel, 2020-2030

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 E-Commerce

10. ADHD Therapeutics Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America ADHD Therapeutics Market Overview
    • 10.1.2 North America ADHD Therapeutics Market Revenue and Forecasts to 2030
    • 10.1.3 North America ADHD Therapeutics Market Revenue and Forecasts and Analysis - By Drug Type
    • 10.1.4 North America ADHD Therapeutics Market Revenue and Forecasts and Analysis - By Age Group
    • 10.1.5 North America ADHD Therapeutics Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 10.1.6 North America ADHD Therapeutics Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States ADHD Therapeutics Market
        • 10.1.6.1.1 United States ADHD Therapeutics Market, by Drug Type
        • 10.1.6.1.2 United States ADHD Therapeutics Market, by Age Group
        • 10.1.6.1.3 United States ADHD Therapeutics Market, by Distribution Channel
      • 10.1.6.2 Canada ADHD Therapeutics Market
        • 10.1.6.2.1 Canada ADHD Therapeutics Market, by Drug Type
        • 10.1.6.2.2 Canada ADHD Therapeutics Market, by Age Group
        • 10.1.6.2.3 Canada ADHD Therapeutics Market, by Distribution Channel
      • 10.1.6.3 Mexico ADHD Therapeutics Market
        • 10.1.6.3.1 Mexico ADHD Therapeutics Market, by Drug Type
        • 10.1.6.3.2 Mexico ADHD Therapeutics Market, by Age Group
        • 10.1.6.3.3 Mexico ADHD Therapeutics Market, by Distribution Channel
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. ADHD Therapeutics Market - Key Company Profiles

  • 13.1 Amneal Pharmaceuticals, Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Novartis AG
  • 13.3 Pfizer, Inc.
  • 13.4 Eli Lilly and Company
  • 13.5 Noven Pharmaceuticals, Inc.
  • 13.6 Janssen Pharmaceuticals, Inc
  • 13.7 Johnson and Johnson Services, Inc.
  • 13.8 Corium Inc
  • 13.9 Adlon Therapeutics L.P
  • 13.10 Teva Pharmaceutical Industries Ltd

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud